Skip to content
Nonprofiteer
← VERSITI BLOOD HEALTH INC

Form 990 for tax year 2024

Filed by VERSITI BLOOD HEALTH INC.

Totals

Total revenue
$281,020,247
Total expenses
$263,641,087
Contributions and grants received
$47,346,648
Grants paid
$4,046,177
Program service revenue
$228,515,997
Investment income
$4,323,810
Other revenue
$833,792
Total assets, end of year
$213,041,862
Total liabilities, end of year
$75,346,695
Net assets or fund balances, end of year
$137,695,167
Program services expenses (Part IX)
$228,452,436
Management and general expenses
$35,188,651
Fundraising expenses
$0
Program service expenses (Part III)
$228,452,436

Program services were 86.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1a · Federated campaigns

    $1,170

  • 1c · Fundraising events

    $65,534

  • 1d · Related organizations

    $10,774,042

  • 1e · Government grants (contributions)

    $32,588,850

  • 1f · All other contributions, gifts and grants

    $3,917,052

  • 2a · Program service revenue: PHARMACY

    total $66,310,411 · related or exempt $66,310,411

  • 2b · Program service revenue: BLOOD SERVICES

    total $54,769,275 · related or exempt $54,769,275

  • 2c · Program service revenue: DIAGNOSTIC LABS

    total $51,114,322 · related or exempt $51,114,322

  • 2d · Program service revenue: ORGAN & TISSUE

    total $26,103,956 · related or exempt $26,103,956

  • 2e · Program service revenue: BIOMATERIALS & TRIALS

    total $17,724,701 · related or exempt $13,745,824 · unrelated business $3,978,877

  • 2f · All other program service revenue

    total $12,493,332 · related or exempt $12,493,332

  • 3 · Investment income

    total $3,849,579 · excluded $3,849,579

  • 6a · Gross rents

    real property $4,483

  • 6b · Less rental expenses

    real property $12,144

  • 6c · Rental income or loss

    real property -$7,661

  • 6d · Net rental income or loss

    total -$7,661 · excluded -$7,661

  • 7a · Gross sales of assets other than inventory

    securities $22,907,473 · other assets $63,159

  • 7b · Less cost or other basis and sales expenses

    securities $22,470,012 · other assets $26,389

  • 7c · Gain or loss

    securities $437,461 · other assets $36,770

  • 7d · Net gain or loss

    total $474,231 · excluded $474,231

  • 8a · Fundraising events: gross income

    $26,200

  • 8a · Fundraising events: contributions included on line 1c

    $65,534

  • 8b · Fundraising events: direct expenses

    $37,690

  • 8c · Net income from fundraising events

    total -$11,490 · excluded -$11,490

  • 11a · Other revenue: AFFILIATE SERVICE FEES

    total $551,381 · excluded $551,381

  • 11b · Other revenue: SHARED SERVICE FEE

    total $228,776 · unrelated business $228,776

  • 11c · Other revenue: ACQUIRED CASH RECEIPTS

    total $66,667 · excluded $66,667

  • 11d · All other revenue

    total $6,119 · related or exempt $2,054 · excluded $4,065

  • 11e · Other revenue, total

    $852,943

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $4,042,177 · program services $4,042,177

  • 2 · Grants to domestic individuals

    total $4,000 · program services $4,000

  • 5 · Compensation of officers, directors and key employees

    total $4,364,390 · program services $2,360,124 · management and general $2,004,266

  • 6 · Compensation of disqualified persons

    total $102,960 · management and general $102,960

  • 7 · Other salaries and wages

    total $84,138,998 · program services $72,439,819 · management and general $11,699,179

  • 8 · Pension plan contributions

    total $4,236,051 · program services $3,596,963 · management and general $639,088

  • 9 · Other employee benefits

    total $13,961,252 · program services $11,754,277 · management and general $2,206,975

  • 10 · Payroll taxes

    total $5,834,264 · program services $4,905,023 · management and general $929,241

  • 11b · Fees: legal

    total $181,659 · program services $61,385 · management and general $120,274

  • 11c · Fees: accounting

    total $83,827 · program services $83,827

  • 11d · Fees: lobbying

    total $66,375 · management and general $66,375

  • 11f · Fees: investment management

    total $5,895 · management and general $5,895

  • 11g · Fees: other

    total $27,035,483 · program services $26,117,290 · management and general $918,193

  • 12 · Advertising and promotion

    total $876,369 · program services $475,391 · management and general $400,978

  • 13 · Office expenses

    total $493,537 · program services $473,267 · management and general $20,270

  • 14 · Information technology

    total $2,661,427 · program services $2,346,892 · management and general $314,535

  • 15 · Royalties

    total $15,727 · program services $15,727

  • 16 · Occupancy

    total $6,611,048 · program services $4,378,606 · management and general $2,232,442

  • 17 · Travel

    total $3,119,840 · program services $2,594,302 · management and general $525,538

  • 19 · Conferences, conventions and meetings

    total $547,720 · program services $473,533 · management and general $74,187

  • 20 · Interest

    total $87,941 · program services $58,178 · management and general $29,763

  • 22 · Depreciation, depletion and amortization

    total $6,659,756 · program services $5,063,766 · management and general $1,595,990

  • 23 · Insurance

    total $99,513 · program services $99,513

  • 24a · Other expenses: COST OF IMPORTED PROD

    total $54,780,339 · program services $54,780,339

  • 24b · Other expenses: MEDICAL LAB SUPPLIES

    total $24,878,103 · program services $24,878,103

  • 24c · Other expenses: VERSITI SERVICES ALLOC

    total $14,610,805 · program services $4,344,313 · management and general $10,266,492

  • 24d · Other expenses: EQUIPMENT LEASE/MAINT

    total $3,621,223 · program services $3,076,794 · management and general $544,429

  • 24e · All other expenses

    total $520,408 · program services $28,827 · management and general $491,581

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $4,778,539 · end of year $4,421,429

  • 2 · Savings and temporary cash investments

    beginning of year $0 · end of year $0

  • 3 · Pledges and grants receivable

    beginning of year $2,528,124 · end of year $12,547,670

  • 4 · Accounts receivable

    beginning of year $38,464,994 · end of year $42,233,253

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0 · end of year $0

  • 8 · Inventories for sale or use

    beginning of year $11,173,130 · end of year $12,095,944

  • 9 · Prepaid expenses and deferred charges

    beginning of year $1,181,467 · end of year $980,278

  • 10a · Land, buildings and equipment: cost or other basis

    $140,723,165

  • 10b · Land, buildings and equipment: accumulated depreciation

    $89,691,845

  • 10c · Land, buildings and equipment, net

    beginning of year $40,808,629 · end of year $51,031,320

  • 11 · Investments: publicly traded securities

    beginning of year $44,952,503 · end of year $46,603,137

  • 12 · Investments: other securities

    beginning of year $17,143,314 · end of year $16,217,402

  • 13 · Investments: program-related

    beginning of year $0 · end of year $0

  • 14 · Intangible assets

    beginning of year $25,991,764 · end of year $24,989,420

  • 15 · Other assets

    beginning of year $1,789,984 · end of year $1,922,009

  • 17 · Accounts payable and accrued expenses

    beginning of year $49,314,606 · end of year $56,506,442

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $3,602,994 · end of year $2,125,503

  • 20 · Tax-exempt bond liabilities

    beginning of year $0 · end of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0 · end of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0 · end of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $15,278,630 · end of year $16,714,750

  • 27 · Net assets without donor restrictions

    beginning of year $120,616,218 · end of year $125,994,810

  • 28 · Net assets with donor restrictions

    beginning of year $0 · end of year $11,700,357

Mission and programs · 2024

Mission

VERSITI WISCONSIN, INC. (VERSITI) IS A BLOOD HEALTH INNOVATOR WHICH ENHANCES LIVES THROUGH DISCOVERY, DIAGNOSIS AND TREATMENT. VERSITI EXPANDS THE FRONTIERS OF PATIENT HEALTH THROUGH THE INTEGRATION OF SCIENCE, MEDICINE AND SERVICE.

Activities or mission (Part I)

(SEE SCHEDULE O)

  • VERSITI OPERATES THE COMPREHENSIVE CENTER FOR BLEEDING DISORDERS (CCBD) UNDER A FEDERAL SUBAWARD AGREEMENT OF THE SOCIAL SECURITY ACT, PROVIDING SPECIALIZED DIAGNOSIS, TREATMENT, AND SUPPORTIVE CARE TO PATIENTS WITH INHERITED AND ACQUIRED BLEEDING AND CLOTTING DISORDERS. AS PART OF VERSITI'S MISSION TO IMPROVE PATIENT OUTCOMES, CCBD DELIVERS COMPREHENSIVE CARE THROUGH A MULTIDISCIPLINARY TEAM OF HEMATOLOGISTS, NURSES, SOCIAL WORKERS, AND SPECIALIZED STAFF. IN 2024, CCBD PROVIDED CRITICAL SERVICES TO PATIENTS WITH BLEEDING DISORDERS AND THEIR FAMILIES, INCLUDING FOR HEMOPHILIA A AND B, VON WILLEBRAND DISEASE, AND OTHER RARE COAGULATION DISORDERS. CCBD PROVIDED 17,470 SPECIALTY PHARMACY PRODUCTS IN 2024 AND CONTINUES TO BE A FEDERALLY RECOGNIZED HEMOPHILIA TREATMENT CENTER (HTC). AS A (CONTINUED IN SCHEDULE O) COVERED ENTITY UNDER THE 340B DRUG DISCOUNT PROGRAM, VERSITI ACCESSES SPECIALTY PHARMACEUTICALS AT DISCOUNTED PRICING, PASSING SAVINGS ON TO PATIENTS AND REDUCING COSTS TO THE HEALTHCARE SYSTEM WHILE ENSURING PHARMACEUTICAL NET INCOME SUPPORTS PROGRAM ACTIVITIES INCLUDING PATIENT CARE, EDUCATION, SUPPORT SERVICES, AND APPROVED RESEARCH. VERSITI PROVIDES THESE SPECIALTY PHARMACY PRODUCTS TO HOME CARE PATIENTS AND HOSPITAL SYSTEMS, IMPROVING MEDICATION ACCESS AND ADHERENCE. THE CENTER'S COMPREHENSIVE SERVICES INCLUDE FACTOR REPLACEMENT THERAPY, PROPHYLACTIC TREATMENT PROTOCOLS, GENETIC COUNSELING, AND PATIENT EDUCATION PROGRAMS DESIGNED TO HELP INDIVIDUALS WITH BLEEDING DISORDERS LIVE FULL, ACTIVE LIVES. THROUGH SPECIALIZED EXPERTISE, FEDERAL PARTNERSHIP, AND COMPASSIONATE CARE, CCBD SERVES AS A PREMIER RESOURCE FOR BLEEDING DISORDER TREATMENT, IMPROVING OUTCOMES WHILE REDUCING HEALTHCARE COSTS FOR PATIENTS WITH THESE COMPLEX CONDITIONS.

    Expenses $58,410,965 · Grants $129,750 · Revenue $66,310,411

  • VERSITI WISCONSIN RECRUITS VOLUNTEER BLOOD DONORS AND COLLECTS, PROCESSES, AND DISTRIBUTES BLOOD PRODUCTS AS PART OF ITS MISSION TO PROVIDE A SAFE AND RELIABLE BLOOD SUPPLY FOR HOSPITALS AND HEALTHCARE SYSTEMS ACROSS WISCONSIN. VERSITI'S COMPREHENSIVE BLOOD INVENTORY INCLUDES RED BLOOD CELLS, PLATELETS, PLASMA, AND SPECIALIZED PRODUCTS DESIGNED TO MEET PATIENT NEEDS. IN 2024, VERSITI WISCONSIN COLLECTED TOTAL RED BLOOD CELLS AND PLATELETS OF 152,765, SERVING 62 HOSPITALS. THE ORGANIZATION HOSTED 2,808 COMMUNITY BLOOD DRIVES, ENGAGING 56,626 VOLUNTEER DONORS WHO CONTRIBUTED TO VERSITI'S LIFESAVING MISSION. (CONTINUED IN SCHEDULE O)INNOVATION AND EMERGENCY RESPONSE: DURING 2024, VERSITI WISCONSIN PARTNERED WITH MILWAUKEE COUNTY TO LAUNCH AN INNOVATIVE EMS PREHOSPITAL WHOLE BLOOD TRANSFUSION PROGRAM FOR CRITICALLY INJURED TRAUMA PATIENTS, THE FIRST SUCH PARTNERSHIP IN WISCONSIN. COMMUNITY PARTNERSHIPS: AS A VITAL PARTNER IN PUBLIC HEALTH, VERSITI WISCONSIN PARTICIPATED IN THE #KNOWSCD SICKLE CELL DISEASE AWARENESS CAMPAIGN, THE WE GIVE BLOOD DRIVE PARTNERSHIP WITH ABBOTT AND THE BIG TEN CONFERENCE DURING THE 2024 FOOTBALL SEASON, AND THE ORGANIZATION'S VERSITI ON KING COMMUNITY CENTER CONDUCTED BLOOD TYPING EVENTS FOR 140 INDIVIDUALS, IDENTIFYING 43 POTENTIAL RO DONORS TO SUPPORT PATIENTS WITH SICKLE CELL DISEASE. INFRASTRUCTURE AND OPERATIONS: VERSITI WISCONSIN OPERATES DONOR CENTERS AND MOBILE COLLECTION UNITS THROUGHOUT THE STATE. IN 2024, THE ORGANIZATION COMPLETED 4 DONOR CENTER RENOVATIONS TO IMPROVE DONOR COMFORT, ENHANCE OPERATIONAL EFFICIENCY, AND EXPAND COLLECTION CAPACITY. THROUGH DEDICATED VOLUNTEER DONORS AND STRATEGIC COMMUNITY PARTNERSHIPS, VERSITI WISCONSIN MAINTAINS A ROBUST BLOOD SUPPLY THAT ENABLES HOSPITALS TO PROVIDE CRITICAL CARE, EMERGENCY SERVICES, AND LIFESAVING TREATMENTS TO PATIENTS THROUGHOUT THE REGION.

    Expenses $47,161,515 · Grants $77,971 · Revenue $54,769,275

  • VERSITI RESEARCH ADVANCES SCIENTIFIC DISCOVERY AND PATIENT CARE THROUGH COMPREHENSIVE SUPPORT OF BLOOD-RELATED RESEARCH, EDUCATION, AND COMMUNITY ENGAGEMENT PROGRAMS. ROOTED IN ITS NONPROFIT MISSION, VERSITI ENABLES GROUNDBREAKING BLOOD RESEARCH WHILE FOSTERING THE NEXT GENERATION OF SCIENTISTS AND IMPROVING THE LIVES OF PATIENTS AFFLICTED BY BLOOD DISORDERS. IN 2024, VERSITI RESEARCHERS PUBLISHED 122 PEER-REVIEWED MANUSCRIPTS WITH 45 FEATURING VBRI FACULTY AS LEAD OR SENIOR AUTHORS, INCLUDING 5 PUBLICATIONS IN JOURNALS WITH IMPACT FACTORS EXCEEDING 30. 7 IN JOURNALS WITH IMPACT FACTORS BETWEEN 20 AND 30, AND 17 IN JOURNALS WITH IMPACT FACTORS BETWEEN 10 AND 20. VERSITI'S RESEARCH SPANS 5 MAJOR PROGRAMS: TRANSFUSION MEDICINE, VASCULAR BIOLOGY, AND CELLULAR THERAPY; THROMBOSIS AND (CONTINUED IN SCHEDULE O) HEMOSTASIS; STEM CELL BIOLOGY AND HEMATOPOIESIS; IMMUNOLOGY; AND TRANSLATIONAL HEMATOLOGY. VERSITI'S RESEARCH GRANT TEAMS PROCESSED APPROXIMATELY $41M IN NEW MULTI-YEAR GRANTS AND SUBMITTED 112 PROPOSALS TOTALING $140.13M IN 2024. VERSITI ALSO LEADS THROUGH COLLABORATIVE BLOOD SCIENCE INITIATIVES SUCH AS IN VENUS (VENOUS THROMBOEMBOLISM NETWORK US) AND REDS-IV-P (RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY), NATIONAL PROGRAMS ADVANCING THROMBOSIS TREATMENT AND BLOOD TRANSFUSION SAFETY. OPERATING IN AN 82,000 SQUARE-FOOT FACILITY, VERSITI IS HOME TO 213 RESEARCH STAFF, INCLUDING 35 INVESTIGATORS AND 22 RESEARCH SCIENTISTS, IN 2024. EDUCATIONAL INITIATIVES INCLUDE GRADUATE TRAINING, RESEARCH SYMPOSIA, AND COLLABORATIVE PARTNERSHIPS IN THE MILWAUKEE REGIONAL MEDICAL CENTER, SUCH AS THE MRMC HEMATOLOGY BIOREPOSITORY, WHICH PROVIDES ANNOTATED BIOLOGICAL SAMPLES FOR BIOMARKER DISCOVERY FOR CLINICAL PARTNERS THROUGHOUT CAMPUS.

    Expenses $39,725,349 · Grants $3,812,500

  • MSI:THE VERSITI MEDICAL SERVICES INSTITUTE (MSI) ADVANCES PATIENT CARE THROUGH SPECIALIZED TREATMENT AND TRANSLATIONAL RESEARCH THAT BRIDGES CLINICAL MEDICINE AND LABORATORY SCIENCE, FOSTERING COLLABORATION BETWEEN PHYSICIAN-SCIENTISTS AND BASIC RESEARCHERS TO ACCELERATE MEDICAL DISCOVERIES. ESTABLISHED IN 2009 AND SUPPORTED BY VERSITI AND THE VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, MSI ENABLES PHYSICIANS TO DEDICATE PROTECTED TIME TO CLINICAL RESEARCH WHILE MAINTAINING PATIENT CARE RESPONSIBILITIES. IN 2024, VERSITI PHYSICIAN-SCIENTISTS PERFORMED 3,686 THERAPEUTIC PROCEDURES. AS PART OF VERSITI'S MISSION TO ADVANCE EVIDENCE-BASED MEDICINE, MSI OPERATES THE CLINICAL TRIALS & RESEARCH OFFICE (CTRO) TO CONDUCT FDA-REGULATED CLINICAL STUDIES IN SPECIALIZED AREAS INCLUDING ALLOIMMUNE PLATELET DISORDERS, TRANSFUSION-INDUCED ACUTE LUNG INJURY, AND DRUG-INDUCED BLOOD DISORDERS. THROUGH MENTORSHIP, PROTECTED RESEARCH TIME, AND COLLABORATIVE INFRASTRUCTURE, MSI PROVIDES DEEP CLINICAL EXPERTISE AND TRANSFORMS CLINICAL QUESTIONS INTO SCIENTIFIC DISCOVERIES THAT BENEFIT PATIENTS WITH BLOOD DISORDERS NATIONWIDE.DONOR TESTING:THE VERSITI DONOR TESTING LABORATORY (DTL) PROVIDES INFECTIOUS DISEASE TESTING TO DETERMINE DONOR SUITABILITY AND PRODUCT SAFETY FOR ORGANS, TISSUES, HEMATOPOIETIC STEM CELLS, AND CORD BLOOD. THE DTL OFFERS NUCLEIC ACID TESTING, ANTIBODY SCREENING, AND CONFIRMATORY TESTING FOR MANY DIFFERENT DISEASE STATES. AS PART OF VERSITI'S MISSION TO MAINTAIN THE SAFEST POSSIBLE BLOOD SUPPLY, DONOR TESTING OPERATIONS CONDUCT MANDATORY SCREENING FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS AS REQUIRED BY FDA REGULATIONS. THE DTL UTILIZES STATE-OF-THE-ART NUCLEIC ACID TESTING (NAT) TECHNOLOGY AND SEROLOGICAL METHODS TO DETECT INFECTIOUS AGENTS. VERSITI'S DTL SUPPORTS BLOOD COLLECTION ACTIVITIES ACROSS VERSITI'S ENTIRE GEOGRAPHIC FOOTPRINT WHILE MAINTAINING RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE. VERSITI'S DONOR TESTING SERVICES STRENGTHEN THE NATIONAL BLOOD SUPPLY INFRASTRUCTURE. BY ENSURING COMPREHENSIVE DONOR SCREENING, VERSITI PROTECTS PATIENTS WHO DEPEND ON SAFE BLOOD TRANSFUSIONS, STRENGTHENS THE NATIONAL BLOOD SUPPLY, AND SUPPORTS THE BROADER PUBLIC HEALTH MISSION OF MAINTAINING CONFIDENCE IN A HIGH-QUALITY BLOOD SUPPLY.DIAGNOSTIC LABS:VERSITI SERVES PATIENTS, PHYSICIANS, AND HOSPITALS BY PROVIDING COMPREHENSIVE CLINICAL DIAGNOSTIC TESTING SERVICES THAT SUPPORT ACCURATE DIAGNOSIS, TREATMENT MONITORING, AND PATIENT CARE ACROSS MULTIPLE MEDICAL SPECIALTIES. AS PART OF VERSITI'S MISSION TO ADVANCE HEALTHCARE THROUGH LABORATORY EXCELLENCE, THE DIAGNOSTIC LABORATORIES DELIVER SPECIALIZED TESTING SERVICES INCLUDING HEMATOLOGY, COAGULATION, IMMUNOHEMATOLOGY, INFECTIOUS DISEASE, MOLECULAR DIAGNOSTICS, FLOW CYTOMETRY, AND REFERENCE LABORATORY SERVICES. DURING 2024, VERSITI CONDUCTED 148,545 DIAGNOSTIC TESTING SERVICES FOR HOSPITALS, PHYSICIAN OFFICES, AND REFERENCE LABORATORIES. VERSITI'S DIAGNOSTIC LABORATORIES MAINTAIN STATE-OF-THE-ART INSTRUMENTATION AND RIGOROUS QUALITY ASSURANCE PROGRAMS TO ENSURE ACCURATE, TIMELY RESULTS THAT GUIDE CLINICAL DECISION-MAKING AND IMPROVE PATIENT OUTCOMES. THE LABORATORIES PROVIDE SPECIALIZED EXPERTISE IN BLOOD-RELATED DISORDERS, OFFERING ADVANCED TESTING CAPABILITIES INCLUDING PLATELET FUNCTION ANALYSIS, COAGULATION STUDIES, RED BLOOD CELL ANTIGEN TYPING, AND COMPLEX IMMUNOHEMATOLOGY WORKUPS THAT CONFIRM AND ENSURE TRANSFUSION SAFETY. VERSITI'S DIAGNOSTIC LABORATORIES SERVE AS A VITAL HEALTHCARE INFRASTRUCTURE RESOURCE, PROVIDING 24/7 TESTING SUPPORT FOR EMERGENCY DEPARTMENTS AND CRITICAL CARE UNITS. THROUGH COMPREHENSIVE DIAGNOSTIC TESTING SERVICES, ADVANCED LABORATORY EXPERTISE, AND COMMITMENT TO QUALITY, VERSITI'S DIAGNOSTIC LABORATORIES STRENGTHEN THE HEALTHCARE SYSTEM BY ENABLING ACCURATE DIAGNOSIS AND OPTIMAL PATIENT CARE ACROSS THE STATE.ORGAN AND TISSUE:VERSITI ORGAN AND TISSUE OPERATES AS SOUTHEASTERN WISCONSIN'S FEDERALLY DESIGNATED ORGAN PROCUREMENT ORGANIZATION, COORDINATING ORGAN AND TISSUE DONATION TO SAVE AND HEAL LIVES THROUGHOUT THE STATE. ROOTED IN VERSITI'S MISSION TO ADVANCE PUBLIC HEALTH, THE ORGANIZATION FACILITATES THE GENEROUS GIFT OF DONATION BY WORKING WITH DONOR FAMILIES, HOSPITALS, AND TRANSPLANT CENTERS TO ENSURE ORGANS AND TISSUES REACH PATIENTS IN NEED. IN 2024, VERSITI ORGAN AND TISSUE COORDINATED 394 ORGAN TRANSPLANTS FROM 606 MUSCULOSKELETAL DONORS. THE ORGANIZATION PROVIDES 24/7 COORDINATION SERVICES, FAMILY SUPPORT, AND CLINICAL EXPERTISE THROUGHOUT THE DONATION PROCESS. VERSITI'S DONATION COORDINATORS AND CLINICAL STAFF WORK ALONGSIDE HOSPITAL TEAMS TO IDENTIFY POTENTIAL DONORS, SUPPORT GRIEVING FAMILIES, AND ENSURE OPTIMAL ORGAN AND TISSUE RECOVERY. THROUGH COMMUNITY EDUCATION PROGRAMS LIKE DONATE LIFE MONTH IN APRIL, VERSITI PROMOTES DONATION AWARENESS AND SUPPORTS WISCONSIN FAMILIES WHO CHOOSE THE HEALING PATH OF DONATION. BY FACILITATING ORGAN AND TISSUE DONATION, VERSITI ORGAN AND TISSUE TRANSFORMS TRAGEDY INTO HOPE, ENABLING ONE DONOR TO SAVE UP TO EIGHT LIVES THROUGH ORGAN DONATION AND HEAL DOZENS MORE THROUGH TISSUE DONATION.VCTS:VERSITI CLINICAL TRIALS SERVICES (VCTS) PROVIDES COMPREHENSIVE CLINICAL RESEARCH SERVICES TO PHARMACEUTICAL SPONSORS, BIOTECHNOLOGY COMPANIES, AND ACADEMIC INSTITUTIONS CONDUCTING CLINICAL STUDIES IN HEMATOLOGY, TRANSFUSION MEDICINE, ONCOLOGY, IMMUNOLOGY, CELL AND GENE THERAPY, AND ORPHAN AND RARE DISEASES. AS PART OF VERSITI'S MISSION TO ADVANCE MEDICAL SCIENCE, VCTS OFFERS SPECIALIZED LABORATORY SERVICES, INSTITUTIONAL REVIEW BOARD (IRB) OVERSIGHT, BIOSPECIMEN COLLECTION AND MANAGEMENT, PROJECT MANAGEMENT, AND REGULATORY SUPPORT TO ENSURE SAFE AND COMPLIANT STUDIES. VCTS LEVERAGES VERSITI'S UNIQUE EXPERTISE IN BLOOD SCIENCE AND LABORATORY DIAGNOSTICS TO SUPPORT COMPLEX TRIALS REQUIRING SPECIALIZED TESTING CAPABILITIES. THE PROGRAM MAINTAINS RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE WHILE PROVIDING INNOVATIVE SOLUTIONS FOR COMPLEX CLINICAL RESEARCH CHALLENGES. THROUGH EXPERT CLINICAL RESEARCH SERVICES, VERSITI CLINICAL TRIALS ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS FOR BLOOD DISORDERS AND SUPPORT THE ADVANCEMENT OF EVIDENCE-BASED MEDICINE IN HEMATOLOGY AND TRANSFUSION MEDICINE.

    Expenses $83,154,607 · Grants $25,956 · Revenue $107,438,365

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Chris Miskel

    PRESIDENT & CEO

    Total calculated
    $1,680,265
    From this org
    $713,940
    From related orgs
    $908,656
    Other
    $57,669
    Hours/week
    23 + 32 related

    Schedule J breakdown matched by us

    Base
    $350,722 + $446,376 related
    Bonus
    $352,309 + $448,395 related
    Other
    $10,909 + $13,885 related
    Deferred
    $10,626 + $13,525 related
    Nontaxable benefits
    $14,748 + $18,770 related
    Filer's total
    $739,314 + $940,951 related

  • Fred Geilfuss

    CHAIR

    Total calculated
    $0
    Hours/week
    1 + 5 related

  • L Alan Whaley

    VICE CHAIR

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Coreen Dicus-Johnson JD

    SECRETARY

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Ron Miller

    TREASURER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Nicholas Bauer

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • David Ginsburg MD

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Cecelia Gore

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Gail Hanson

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Thomas Hauske Jr

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Sherry Husa

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Dale Kent

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Robert H Manegold

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 5 related

  • Jeffrey S McDonald

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Maggey Oplinger

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • John Perras

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Kathy Thornton-Bias

    BOARD MEMBER - THRU 6/24

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Greg Wesley

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Peter Ziegler

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1 + 4 related

  • Matthew Anderson MD

    EVP & CHIEF MED. OFF. - AS OF 7/24

    Total calculated
    $537,718
    From this org
    $471,868
    From related orgs
    $0
    Other
    $65,850
    Hours/week
    50 + 5 related

    Schedule J breakdown matched by us

    Base
    $403,926
    Bonus
    $65,100
    Other
    $2,842
    Deferred
    $24,150
    Nontaxable benefits
    $41,700
    Filer's total
    $537,718

  • Brian Bautista

    EVP & CHIEF OPERATING OFFICER

    Total calculated
    $866,357
    From this org
    $357,615
    From related orgs
    $455,150
    Other
    $53,592
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $204,932 + $260,825 related
    Bonus
    $143,060 + $182,076 related
    Other
    $9,623 + $12,249 related
    Deferred
    $8,081 + $10,285 related
    Nontaxable benefits
    $15,499 + $19,727 related
    Filer's total
    $381,195 + $485,162 related

  • Lynne Briggs

    VP & CHIEF INFORMATION OFFICER

    Total calculated
    $534,488
    From this org
    $212,020
    From related orgs
    $269,846
    Other
    $52,622
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $141,179 + $179,684 related
    Bonus
    $67,763 + $86,243 related
    Other
    $3,078 + $3,919 related
    Deferred
    $11,595 + $14,758 related
    Nontaxable benefits
    $11,558 + $14,711 related
    Filer's total
    $235,173 + $299,315 related

  • Barbara Bryant

    EVP & CHIEF MED. OFF. - THRU 8/24

    Total calculated
    $473,670
    From this org
    $447,822
    From related orgs
    $0
    Other
    $25,848
    Hours/week
    50 + 5 related

    Schedule J breakdown matched by us

    Base
    $328,620
    Bonus
    $101,700
    Other
    $17,502
    Deferred
    $23,946
    Nontaxable benefits
    $1,902
    Filer's total
    $473,670

  • Michael Deininger MD

    EVP & CHIEF SCIENTIFIC OFFICER

    Total calculated
    $709,841
    From this org
    $637,080
    From related orgs
    $33,530
    Other
    $39,231
    Hours/week
    48 + 7 related

    Schedule J breakdown matched by us

    Base
    $497,386 + $26,178 related
    Bonus
    $112,195 + $5,905 related
    Other
    $27,499 + $1,447 related
    Deferred
    $15,090 + $794 related
    Nontaxable benefits
    $22,180 + $1,167 related
    Filer's total
    $674,350 + $35,491 related

  • Jessica Drouillard

    VP & CHIEF QUALITY OFFICER

    Total calculated
    $294,942
    From this org
    $121,455
    From related orgs
    $154,582
    Other
    $18,905
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $86,807 + $110,482 related
    Bonus
    $24,376 + $31,024 related
    Other
    $10,272 + $13,076 related
    Deferred
    $6,776 + $8,624 related
    Nontaxable benefits
    $1,543 + $1,962 related
    Filer's total
    $129,774 + $165,168 related

  • Gitesh Dubal

    EVP & CHIEF MKTG. OFF. - THRU 4/24

    Total calculated
    $430,841
    From this org
    $179,108
    From related orgs
    $227,952
    Other
    $23,781
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $56,655 + $72,103 related
    Bonus
    $113,676 + $144,678 related
    Other
    $8,777 + $11,171 related
    Deferred
    $4,651 + $5,920 related
    Nontaxable benefits
    $5,813 + $7,397 related
    Filer's total
    $189,572 + $241,269 related

  • Gretchen Jameson

    EVP & CHIEF MKTG. OFF. - AS OF 4/24

    Total calculated
    $235,428
    From this org
    $96,983
    From related orgs
    $123,432
    Other
    $15,013
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $96,463 + $122,769 related
    Bonus
    $0
    Other
    $520 + $663 related
    Deferred
    $6,042 + $7,689 related
    Nontaxable benefits
    $563 + $719 related
    Filer's total
    $103,588 + $131,840 related

  • Bradley Pietz

    EVP & CHIEF LABORATORY OFFICER

    Total calculated
    $666,345
    From this org
    $264,400
    From related orgs
    $336,515
    Other
    $65,430
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $135,259 + $172,151 related
    Bonus
    $117,801 + $149,929 related
    Other
    $11,340 + $14,435 related
    Deferred
    $10,538 + $13,413 related
    Nontaxable benefits
    $18,251 + $23,228 related
    Filer's total
    $293,189 + $373,156 related

  • Bart Reuter

    EVP & GENERAL COUNSEL

    Total calculated
    $927,646
    From this org
    $379,102
    From related orgs
    $482,498
    Other
    $66,046
    Hours/week
    23 + 32 related

    Schedule J breakdown matched by us

    Base
    $189,439 + $241,106 related
    Bonus
    $178,380 + $227,030 related
    Other
    $11,283 + $14,362 related
    Deferred
    $10,626 + $13,525 related
    Nontaxable benefits
    $18,433 + $23,462 related
    Filer's total
    $408,161 + $519,485 related

  • Derek Tyus

    EVP & CHIEF FINANCIAL OFF. - AS 3/24

    Total calculated
    $500,657
    From this org
    $199,013
    From related orgs
    $253,291
    Other
    $48,353
    Hours/week
    23 + 32 related

    Schedule J breakdown matched by us

    Base
    $144,868 + $184,379 related
    Bonus
    $52,800 + $67,200 related
    Other
    $1,345 + $1,712 related
    Deferred
    $10,425 + $13,268 related
    Nontaxable benefits
    $10,851 + $13,809 related
    Filer's total
    $220,289 + $280,368 related

  • Anthony Watkins

    EVP&CFO-THRU 3/24;BUS DEV-AS OF 3/24

    Total calculated
    $778,587
    From this org
    $329,433
    From related orgs
    $419,278
    Other
    $29,876
    Hours/week
    23 + 32 related

    Schedule J breakdown matched by us

    Base
    $144,004 + $183,278 related
    Bonus
    $155,980 + $198,520 related
    Other
    $29,449 + $37,480 related
    Deferred
    $10,626 + $13,525 related
    Nontaxable benefits
    $2,518 + $3,207 related
    Filer's total
    $342,577 + $436,010 related

  • James Weidner

    EVP & CHIEF HR OFFICER

    Total calculated
    $628,394
    From this org
    $251,504
    From related orgs
    $320,098
    Other
    $56,792
    Hours/week
    24 + 31 related

    Schedule J breakdown matched by us

    Base
    $140,199 + $178,436 related
    Bonus
    $100,156 + $127,471 related
    Other
    $11,149 + $14,191 related
    Deferred
    $10,626 + $13,525 related
    Nontaxable benefits
    $14,361 + $18,280 related
    Filer's total
    $276,491 + $351,903 related

  • Kathleen Puca

    SR MEDICAL DIRECTOR

    Total calculated
    $498,057
    From this org
    $442,557
    From related orgs
    $0
    Other
    $55,500
    Hours/week
    55

    Schedule J breakdown matched by us

    Base
    $345,435
    Bonus
    $67,100
    Other
    $30,022
    Deferred
    $27,600
    Nontaxable benefits
    $27,900
    Filer's total
    $498,057

  • Karin Hoffmeister

    DEPUTY DIRECTOR VBRI

    Total calculated
    $460,374
    From this org
    $411,046
    From related orgs
    $0
    Other
    $49,328
    Hours/week
    55

    Schedule J breakdown matched by us

    Base
    $353,991
    Bonus
    $41,800
    Other
    $15,255
    Deferred
    $14,309
    Nontaxable benefits
    $35,019
    Filer's total
    $460,374

  • Christian J Kastrup PhD

    SR INVESTIGATOR

    Total calculated
    $461,101
    From this org
    $399,219
    From related orgs
    $0
    Other
    $61,882
    Hours/week
    55

    Schedule J breakdown matched by us

    Base
    $377,833
    Bonus
    $19,900
    Other
    $1,486
    Deferred
    $20,250
    Nontaxable benefits
    $41,632
    Filer's total
    $461,101

  • Lynn M Malec MD

    SENIOR MEDICAL DIRECTOR

    Total calculated
    $419,137
    From this org
    $384,247
    From related orgs
    $0
    Other
    $34,890
    Hours/week
    55

    Schedule J breakdown matched by us

    Base
    $361,479
    Bonus
    $18,100
    Other
    $4,668
    Deferred
    $17,926
    Nontaxable benefits
    $16,964
    Filer's total
    $419,137

  • Lisa Baumann Kreuziger

    SENIOR MEDICAL DIRECTOR

    Total calculated
    $435,514
    From this org
    $394,936
    From related orgs
    $0
    Other
    $40,578
    Hours/week
    55

    Schedule J breakdown matched by us

    Base
    $345,859
    Bonus
    $23,800
    Other
    $25,277
    Deferred
    $24,150
    Nontaxable benefits
    $16,428
    Filer's total
    $435,514

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 3
TOP MANAGEMENT'S COMPENSATION THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, ACTING IN ITS CAPACITY AS THE COMPENSATION COMMITTEE, SETS AND MONITORS THE COMPENSATION PHILOSOPHY FOR THE FILING ORGANIZATION. OTHER THAN THE VERSITI PRESIDENT AND CHIEF EXECUTIVE OFFICER, THE EXECUTIVE COMMITTEE DOES NOT INCLUDE MEMBERS OF MANAGEMENT. TO ENSURE THAT THE COMMITTEE IS COMPRISED OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO VERSITI COMPENSATION ARRANGEMENTS, THE VERSITI PRESIDENT AND CHIEF EXECUTIVE OFFICER RECUSES HER/HIMSELF FROM ALL DISCUSSIONS AND APPROVALS RELATED TO HER/HIS COMPENSATION. THE EXECUTIVE COMMITTEE REVIEWS EXECUTIVE COMPENSATION ARRANGEMENTS TO ENSURE SUCH ARRANGEMENTS ARE FAIR, REASONABLE, AND NOT EXCESSIVE WHEN COMPARED TO SIMILARLY-SITUATED EXECUTIVES. EXECUTIVE COMPENSATION ARRANGEMENTS ARE REVIEWED FOR REASONABLENESS AND APPROVED BY THE EXECUTIVE COMMITTEE ANNUALLY IN ACCORDANCE WITH THE VERSITI REASONABLENESS REVIEW POLICY. IN ORDER TO ASSESS THE REASONABLENESS OF EXECUTIVE COMPENSATION ARRANGEMENTS, THE EXECUTIVE COMMITTEE OBTAINS AND REVIEWS APPROPRIATE COMPARABILITY DATA COLLECTED BY THE HUMAN RESOURCE DEPARTMENT AND/OR A QUALIFIED INDEPENDENT COMPENSATION CONSULTANT. THE EXECUTIVE COMMITTEE ENGAGES A QUALIFIED INDEPENDENT COMPENSATION CONSULTANT ANNUALLY. THE INDEPENDENT CONSULTANT PERFORMS AN ANALYSIS OF COMPENSATION LEVELS AT REGIONAL AND NATIONAL ORGANIZATIONS OF COMPARABLE SIZE, SCOPE AND STRUCTURE; AND PROVIDES THE COMMITTEE WITH COMPREHENSIVE DATA ON THE AVAILABILITY OF SIMILAR SERVICES WITHIN THE GEOGRAPHIC AREA, COMPENSATION SURVEYS, WRITTEN OFFERS FROM SIMILAR INSTITUTIONS, AND OTHER INFORMATION RELEVANT TO COMPARABILITY OF COMPENSATION. THE EXECUTIVE COMMITTEE'S REVIEW, RECOMMENDATIONS AND APPROVALS ARE DOCUMENTED CONCURRENTLY IN THE COMMITTEE MINUTES, WHICH ARE SUBSEQUENTLY REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AS REASONABLE, ACCURATE AND COMPLETE. THE COMMITTEE CHAIR VERBALLY COMMUNICATES TO THE BOARD OF DIRECTORS A CONFIRMATION OF COMPENSATION REASONABLENESS AND THE OVERALL DUE DILIGENCE PROCESS. VERSITI WISCONSIN HAS INCENTIVE PROGRAMS FOR EXECUTIVES, DIRECTORS, MANAGEMENT, INVESTIGATORS AND STAFF DESCRIBED IN DETAILED WRITTEN POLICIES APPROVED BY THE EXECUTIVE COMMITTEE ANNUALLY. EVALUATION AND COMPENSATION REVIEW -CEO - EACH YEAR, THE EXECUTIVE COMMITTEE EVALUATES THE CEO'S PERFORMANCE AGAINST ESTABLISHED OBJECTIVES, DETERMINES INCENTIVE PAYMENT AND MERIT INCREASE BASED UPON PERFORMANCE AND MARKET DATA PROVIDED BY THE THIRD PARTY COMPENSATION CONSULTANT, AND WORKS WITH THE CEO TO ESTABLISH OBJECTIVES FOR THE NEXT YEAR. -EXECUTIVES - THE BOARD OF DIRECTORS HAS DELAGATED TO THE CEO THE PERFORMANCE ASSESSMENT AND COMPENSATION DECISIONS FOR HIS/HER TEAM AND LEADERS ELIGIBLE FOR THE VERSITI LEADERSHIP INCENTIVE PLAN. DURING THE MAY MEETING, THE EXECUTIVE COMMITTEE REVIEWS THE INCENTIVES (SHORT AND LONG-TERM) PAYOUTS AND MERIT INCREASES ASSIGNED TO THE EXECUTIVE TEAM AS PART OF THE ANNUAL COMPENSATION REASONABILITY REVIEW CONDUCTED BY AON CONSULTANTS. THE EXECUTIVE COMMITTEE REVIEWS AND APPROVES THE SALARY INCREASES AND INCENTIVE PAYOUTS OF THE CEO BEFORE PAYMENT. EXECUTIVES ARE POSITIONED WITHIN THE APPROPRIATE SALARY RANGE BASED UPON THE: -EXECUTIVE'S KNOWLEDGE, COMPETENCIES, AND EXPERIENCE, -PERFORMANCE OF THE EXECUTIVE'S AREAS OF RESPONSIBILITY, -THE EXECUTIVE'S CONTRIBUTION TO OVERALL PERFORMANCE, -THE IMPORTANCE OF RETAINING THE EXECUTIVE, -INTERNAL EQUITY CONSIDERATIONS, -THE FINANCIAL RESOURCES AVAILABLE, AND -EXECUTIVE BASE SALARY INCREASES PROVIDED IN THE COMPETITIVE MARKET.
PART I, LINE 5A, 5B, 6A, 6B AND 7:
NON-FIXED PAYMENTS INCENTIVE PAYOUT OPPORTUNITIES, BASED ON PERCENTAGE OF BASE PAY RATE, ARE AVAILABLE TO CERTAIN EMPLOYEES OF THE FILING ORGANIZATION. WHILE LEVELS OF THE INCENTIVE PAYOUT OPPORTUNITY ARE FIXED AND DETERMINED PERCENTAGES OF BASE COMPENSATION, THE INCENTIVE PAYOUT IS DETERMINED, IN PART, ON THE CONSOLIDATED REVENUE AND NET EARNINGS OF OPERATING DIVISIONS. THE INCENTIVE PAYOUT IS SUBJECT TO THE REVIEW OF ACCOMPLISHMENTS/OBJECTIVES AND THE ULTIMATE DETERMINATION OF INCENTIVE COMPENSATION IS SUBJECT TO PRESIDENT/CEO AND EXECUTIVE COMMITTEE OF THE BOARD APPROVAL.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • RCRC INDEPENDENT REVIEW BOARD LLC

    REVIEW BOARD · TX · income $5,691,154 · assets $4,567,553

    Directly controlled by VERSITI WI

  • QUANTIGEN LLC

    SPECIALTY LAB SERVICES · IN · income $8,575,322 · assets $22,717,169

    Directly controlled by VERSITI WI

  • PEARL IRB LLC

    REGULATORY AFFAIRS CONSULTING SERVICES · IN · income $3,994,527 · assets $11,401,801

    Directly controlled by VERSITI WI

Related corporations and trusts

Part IV: related organizations taxable as a corporation or trust.

  • CENETRON DIAGNOSTICS LLC

    C · LABS & TRIALS · TX · 100% owned · share of income $504,088 · share of assets $20,800,182 · controlled entity

    Directly controlled by VERSITI WI

Provenance

Return type
form_990
Tax year
2024
Filed
11 November 2025
IRS schema version
2024v5.2
Source object
202513159349304706

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.